Comparison · NCT00059202-1bdcedeb
Ursodeoxycholic Acid vs Placebo: Number of Participants With Treatment Failure
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ursodeoxycholic Acid vs Placebo: Number of Participants With Treatment Failure. Trial comparisons, record NCT00059202-1bdcedeb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00059202-1bdcedeb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.395 | 0.292 | 0.507 | wilson | |
| Risk in group 2 | 0.257 | 0.171 | 0.367 | wilson | |
| Risk difference, group 1 minus group 2 | 0.138 | -0.0121 | 0.279 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.54 | 0.954 | 2.48 | log | |
| Odds ratio, group 1 over group 2 | 1.89 | 0.942 | 3.78 | log | |
| Number needed to treat, for one more participant with the outcome on Ursodeoxycholic Acid than on Placebo | 7.25 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ursodeoxycholic Acid | Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses | 30 | 76 | OG000 |
| Group 2 | Placebo | Placebo for Urso | 19 | 74 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Treatment Failure
- Description
- Treatment failure was defined as death, transplantation, meeting minimal listing criteria, development of varices, cholangiocarcinoma, or progression to cirrhosis
- Time frame
- 5 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Trial of High-dose Urso in Primary Sclerosing Cholangitis
- NCT number
- NCT00059202
- Phases
- PHASE2, PHASE3
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Ursodeoxycholic Acid, Placebo
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Results first posted
- 2021-04-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00059202?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00059202-1bdcedeb